Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy (JSGOE) Guidelines for Endoscopic Surgery in Obstetrics and Gynecology [6] reports that the oral GnRH antagonist relugolix available in 2019 can now be prescribed to treat patients with uterine fibroids. Here, GNRH1 is linked to uterine corpus leiomyoma.